HIF1A and non-small cell lung carcinoma: Canagliflozin, through AMPK activation and mTOR inhibition, downregulates HIF-1α, hence inhibiting the proliferation of non-small cell lung cancer (NSCLC) and improving the efficacy of radiation therapy (Biziotis et al. 2023).